IPB-107

About Interplay Bio

Interplay Bio is an early-stage biotech leveraging its LigandPro platform to pioneer Targeted Protein Degradation (TPD) drug discovery. The company's core technology identifies small molecule ligands that bind to diverse protein surfaces, including non-traditional pockets, to enable the degradation of challenging targets. With a pipeline of early-stage candidates and a focus on collaboration, Interplay Bio is positioning itself to address high-need therapeutic areas like oncology and neurodegenerative diseases. The company is currently pre-revenue and seeking partnerships to advance its programs.

Therapeutic Areas

Other Pancreatic Ductal Adenocarcinoma (PDAC) Drugs